Adherence to ruxolitinib, an oral JAK1/2 inhibitor, in patients with myelofibrosis: interim analysis from an Italian, prospective cohort study (ROMEI).
Guglielmelli P, Palandri F, Selleri C, Cilloni D, Mendicino F, Mazza P, Pastore D, Palumbo GA, Santoro M, Pavone V, Impera S, Morelli M, Coco P, Valsecchi D, Passamonti F, Breccia M; ROMEI study group.
Guglielmelli P, et al. Among authors: valsecchi d.
Leuk Lymphoma. 2022 Jan;63(1):189-198. doi: 10.1080/10428194.2021.1969388. Epub 2021 Sep 15.
Leuk Lymphoma. 2022.
PMID: 34521299